Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) has announced a conference call scheduled for August 1, 2024, at 4:30 p.m. Eastern Time to discuss its second quarter 2024 financial results and provide a business update. Interested parties can participate by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international) and asking to join the Ardelyx call. A live audio webcast will be available on the company's website under the Investors section, with a 30-day archive available after the call. Ardelyx is a biopharmaceutical company focused on developing innovative, first-in-class medicines for significant unmet medical needs.

Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, August 1, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2024.

To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

When will Ardelyx (ARDX) report its Q2 2024 financial results?

Ardelyx (ARDX) will report its second quarter 2024 financial results on August 1, 2024, during a conference call scheduled for 4:30 p.m. Eastern Time.

How can investors participate in Ardelyx's (ARDX) Q2 2024 earnings call?

Investors can participate in Ardelyx's (ARDX) Q2 2024 earnings call by dialing (844) 481-2838 for domestic callers or (412) 317-1858 for international callers and asking to join the Ardelyx call.

Where can I find the webcast for Ardelyx's (ARDX) Q2 2024 earnings call?

The live audio webcast for Ardelyx's (ARDX) Q2 2024 earnings call will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived for 30 days following the call.

What is the focus of Ardelyx (ARDX) as a biopharmaceutical company?

Ardelyx (ARDX) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines that meet significant unmet medical needs.